Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008

References

• NordlingerBSorbyeHColletteLFinal results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially respectable colorectal cancer liver metastasesProc Am Soc Clin Oncol200725LBA5
   Web of Science ®Google Scholar
• NordlingerBPeri-operative FOLFOX4 chemotherapy and surgery for resectable liver metastases from colorectal cancer: Final efficacy results of the EORTC Intergroup phase III study 40983 [slide presentation]Presented at Proceedings of the American Society of Clinical Oncology 43rd Annual MeetingJune 1–5 2007Chicago, IL
   Google Scholar
• De GramontAOxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of 6 years [slide presentation]Presented at Proceedings of the American Society of Clinical Oncology 43rd Annual MeetingJune 1–5, 2007Chicago, IL, USA
   Google Scholar
• De GramontABoniCNavarroMOxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six yearsProc Am Soc Clin Oncol2007254007
   Web of Science ®Google Scholar
• Van CutsemENowackiMLangIRandomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trialProc Am Soc Clin Oncol2007254000
   Google Scholar
• BensonABBest of ASCO: gastrointestinal (colorectal) cancer [slide presentation]Presented at Proceedings of the American Society of Clinical Oncology 43rd Annual MeetingJune 1–5, 2007Chicago, IL, USA
   Google Scholar
• GremJ2007Best of ASCO gastrointestinal (colorectal) cancer [slide presentation on the Internet]2007Alexandria (VA)American Society of Clinical Oncology [Cited on April 30, 2008]. Available from: http://asco.org/portal/site/ASCO/menuitem.64cfbd0f85cb37b2eda2be0aee37a01d?vgnextoid=09f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=vm_meeting_tracks_view&index=y&confID=51
   Google Scholar
• LievreABachetJBBoigeVKRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximabJ Clin Oncol20082637437918202412
   PubMed Web of Science ®Google Scholar
• LievreABachetJBLe CorreDKRAS mutation status is predictive of response to cetuximab therapy in colorectal cancerCancer Res2006663992399516618717
   PubMed Web of Science ®Google Scholar
• Van CutsemELangID’haensGKRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experienceProc Am Soc Clin Oncol2008262
   Web of Science ®Google Scholar
• EngCImpact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: Results from the EPIC trial [slide presentation]Presented at Proceedings of the American Society of Clinical Oncology 43rd Annual MeetingJune 1–5, 2007Chicago, IL, USA
   Google Scholar
• EngCMaurelJScheithauerWImpact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trialProc Am Soc Clin Oncol2007254003
   Google Scholar
• AuHKarapetisCJonkerDQuality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trialProc Am Soc Clin Oncol2007254002
   Google Scholar
• AuHQuality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial [slide presentation]Presented at Proceedings of the American Society of Clinical Oncology 43rd Annual MeetingJune 1–5, 2007Chicago, IL, USA
   Google Scholar
• BokemeyerCBondarenkoIMakhsonACetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II studyProc Am Soc Clin Oncol2007254035
   Google Scholar
• BokemeyerCCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of mCRC: OPUS, a phase II study [slide presentation]Presented at Proceedings of the American Society of Clinical Oncology 43rd Annual MeetingJune 1–5, 2007Chicago, IL, USA
   Google Scholar
• TaberneroJVan CutsemEDíaz-RubioEPhase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancerJ Clin Oncol2007255225523218024868
   PubMed Web of Science ®Google Scholar
• BokemeyerCBondarenkoIHartmannJTKRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experienceProc Am Soc Clin Oncol2008264000
   Web of Science ®Google Scholar
• ChungCHChanEBerlinJCetuximab-related hypersensitivity reactions associated with pre-existing cetuximab-specific IgE antibodyProc Am Soc Clin Oncol2007259097
   Web of Science ®Google Scholar
• FuchsCMarshallJMitchellEUpdated results of BICC-C study comparing first-line irinotecan/fluoropyrmidine combinations with or without celecoxib in mCRC: Updated efficacy dataProc Am Soc Clin Oncol2007254027
   Web of Science ®Google Scholar
• FuchsCSMarshallJMitchellERandomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C studyJ Clin Oncol2007254779478617947725
   PubMed Web of Science ®Google Scholar
• GrotheyASargentDGoldbergRMSchmollHJSurvival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatmentJ Clin Oncol2004221209121415051767
   PubMed Web of Science ®Google Scholar
• PuntCJKoopmanMDoumaJSequential compared to combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (ACC): a Dutch Colorectal Cancer Group (DCCG) phase III studyProc Am Soc Clin Oncol2007254012
   Google Scholar
• KoopmanMAntoniniNFDoumaJSequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trialLancet200737013514217630036
   PubMed Web of Science ®Google Scholar
• SeymourMTMaughanTSLedermannJAFOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies GroupDifferent strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trialLancet2007370143152 Erratum in: Lancet 2007; 370:566.17630037
   PubMed Web of Science ®Google Scholar
• GrotheyASugrueMHedrickEAssociation between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)Proc Am Soc Clin Oncol2007254036
   Web of Science ®Google Scholar
• FrancoisEChamoreyEBerdahJPhase II assessing irinotecan (CPT11) plus 5-fluorouracil (5FU) and leucovorin (FOLFIRI regimen) as first-line chemotherapy for elderly patients with metastatic colorectal cancerProc Am Soc Clin Oncol200725314
   Google Scholar
• FolprechtGSeymourMTSaltzLIrinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trialsProc Am Soc Clin Oncol2007254071
   Google Scholar